Hem n Onc 8-7 (8) Flashcards
This patient presents with excessive bleeding from the nose and gums along with small, pinpoint areas of bleeding within the skin (petechiae). He is tired and has lost a significant amount of weight. His lab tests show elevated prothrombin time (PT), bleeding time (BT), and partial thromboplastin time (PPT) and decreased fibrinogen. Taken together, these clues suggest that the patient is experiencing?
disseminated intravascular coagulation (DIC). DIC is characterized by significant abnormalities in coagulation and can clinically manifest with both excess bleeding and thrombosis.
The findings of leukemia plus DIC are most commonly associated with APL, a variant of AML. The characteristic chromosomal translocation of?
AML is t(15;17).
The t(8;14) translocation is characteristic of Burkitt lymphoma, which manifests most commonly as an isolated enlarging mass. The t(9;22) translocation, also known as the Philadelphia chromosome, is associated with chronic myelogenous leukemia. The t(11;14) translocation is characteristic of ?
mantle cell lymphoma. The t(12;21) translocation is commonly seen in acute lymphoblastic leukemia.
This patient’s combination of “B”-symptoms (fever, weight loss, fatigue) and a hard neck mass with a t([14;18]) translocation is diagnostic for follicular lymphoma. The chromosomal translocation (t[14;18]) results in upregulation of the antiapoptotic factor Bcl-2. Bcl-2, along with Bcl-xL, prevents the release of cytochrome c and stops it from binding to APAF-1 and activating the caspase cascade, which results in apoptosis. In B-lymphocyte malignancies, particularly follicular lymphoma, upregulation of bcl-2 resulting from a?
chromosomal translocation (t[14;18]) then acts to confer a survival benefit to otherwise dying cells and promotes malignant transformation.
he translocation t(14;18) causes increased activity of Bcl-2, an?
antagonist of apoptotic cell death, making a patient more susceptible to follicular lymphoma and other B-lymphocyte malignancies.
Upregulation of the cell cycle results from inappropriate activation of the protein coded by c-Myc, a transcription factor that drives cell proliferation.
TP53 is a cell cycle inhibitor in response to the detection of a DNA error. If repair is not possible, the gene p53 then initiates apoptosis. A mutation in p53 is found in numerous cancers, including colon cancer and B-lymphocyte lymphoma.
Agonism of apoptosis is carried out by BAX, BAK, and other proapoptotic proteins. When repair of DNA is not possible, these proteins allow the release of caspase-activating proteins from the mitochondria to trigger cell death.
Constitutive activation of G proteins, such as the RAS protein, is seen in many cancers. Activation of RAS is seen in?
neurofibromatosis.
Inactivation of p53 occurs in a number of cancers. p53 functions as a tumor suppressor gene, so loss of p53 confers a cellular state that supports progression to malignancy.
This patient’s history of painful episodes requiring hospitalization should raise suspicion for sickle cell disease. Patients with sickle cell disease tend to present at a young age with painful vaso-occlusive crises, which occur when sickled RBCs occlude capillaries and restrict blood flow. Autosplenectomy typically occurs in sickle cell patients by this patient’s age as a result of repeated splenic infarcts. Patients with impaired splenic function are susceptible to infection by encapsulated organisms such as Salmonella typhi. This is because the spleen is rich in macrophages that can recognize and clear complement- or IgG-coated sugar-rich capsules. The symptoms suggest that the boy has?
osteomyelitis of the tibia, and the most important determinant of virulence in sickle cell patients with osteomyelitis is the presence of a bacterial capsule. Staphylococcus aureus is the most common cause of osteomyelitis in all groups, but Salmonella osteomyelitis has a particular association with sickle cell disease, and it is this association that is often tested on the Step 1 USMLE.
While bacterial pili do allow cells to adhere to surfaces in hosts, they are not a virulence factor allowing Salmonella to cause osteomyelitis.
Mycolic acids are components of the outer mycobacterial membrane and are not found in Salmonella capsules.
Flagella allows for motility but does not explain?
the enhanced virulence of Salmonella in sickle cell disease.
Mycoplasma species do not have a cell wall, but this does not contribute to enhanced virulence in sickle cell patients.
The patient presents with weight loss, signs of anemia, generalized lymphadenopathy, and hepatosplenomegaly, which strongly suggests a non-Hodgkin lymphoma. Systemic symptoms of Hodgkin lymphoma may include “B” symptoms, such as fever, weight loss, and drenching night sweats. These symptoms—which can be seen in both Hodgkin and non-Hodgkin lymphoma—are observed in approximately 40% of patients with non-Hodgkin lymphoma and are a poor prognostic indicator. Non-Hodgkin lymphoma often involves ?
multiple lymph nodes, while extranodal involvement is also common. One risk factor for non-Hodgkin lymphoma is immunosuppression.
Neoplastic B lymphocytes are the cells of origin in most non-Hodgkin lymphomas (90% of cases). The subtypes of non-Hodgkin lymphomas include Burkitt lymphoma, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and marginal zone lymphoma. Approximately 10% of lymphomas are Hodgkin lymphomas.
Acute myelogenous and promyelocytic leukemia feature increases in myeloblasts. Acute promyelocytic leukemia is caused by a t(15;17) mutation and features symptoms of marrow failure, such as anemia and thrombocytopenia, along with splenomegaly and bleeding from the gums.
Plasma cells are mutated and overactive in multiple myeloma, which can present with hypercalcemia, generalized weakness, and renal failure.
Reed-Sternberg cells are CD15 and CD30 positive neoplastic cells in Hodgkin lymphoma, which can present with?
fever, night sweats, and localized lymphadenopathy, unlike the generalized lymphadenopathy of non-Hodgkin lymphoma.
T-cell lymphomas such as Sézary syndrome and T-cell lymphoblastic leukemia can present with a mediastinal mass.
The prevalence is the number of individuals with a disease in a given population at risk for that particular disease at a given time. Prevalence can be estimated in cross-sectional studies, in which the disease (breast mass) is compared with an exposure (history of estrogen therapy). In the chart, the prevalence can be determined by calculating the number of patients with a breast mass (W + Y) divided by ?
the total number of people in the population (W + X + Y + Z), or (W + Y)/(W + X + Y + Z).
(W + X) / (W + X + Y + Z) is the proportion of the population who are exposed to hormone therapy.
W/(W +Y) is a proportion of breast cancer patients who are exposed to hormone therapy.
Z/(Z + X) s the proportion of patients with no breast mass that also had not been exposed to hormone therapy.
W/(W + X) is the?
proportion of those exposed to hormone therapy who have a breast mass.
Among both sexes, lung cancer is by far the leading cause of cancer mortality (33% of cancer deaths for men and 23% for women). Adenocarcinoma, characterized by glandular differentiation and frequently stains mucin positive (shown in the image), is ?
a common type of lung cancer. It is the most common type of lung cancer in women.
Adenomatous lesions invading the submucosa and muscularis propria describe colorectal cancer, the third leading cause of cancer-related deaths in the United States among both men and women.
In women, breast cancer is the leading cause of cancer and the second most common cause of cancer deaths. Breast cancer includes ductal carcinoma in situ, which presents as?
malignant cells limited to ducts and lobules. Cyst with microscopic papillae and psammoma bodies describe serous ovarian carcinoma, and ovarian cancers represent the fifth leading cause of cancer deaths in women.
Lastly, HPV infection of the cervix can lead to koilocytotic atypia, which would predispose to cervical cancer, which is not a leading cause of cancer mortality in women. Deaths from cervical cancer have dramatically fallen since screening by Papanicolaou smear was introduced.
This patient presents with a scaling, indurated, ulcerated nodule below the lower lip. A biopsy of the lesion is sent to pathology. Squamous cell carcinoma (SCC) commonly appears on the face, especially around the lips. It more commonly occurs around the lower lip, whereas basal cell carcinoma is more frequently seen on and around the upper lip. Even with these clinical clues, biopsy is still required for a definitive diagnosis.
On biopsy of SCC, keratinization is often evident (as shown in this image). This type of cancer is locally invasive, but rarely metastatic. Sun exposure is?
the primary cause of SCC, but industrial carcinogens such as tars and oils, old burn scars, arsenic, and exposure to ionizing radiation are also risk factors. Grossly, SCC appears as a scaly, erythematous, ulcerated lesion with irregular borders, as seen in the image below.